Effective Collaboration - Team Research for Better Returns: Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Effective Collaboration - Team Research for Better Returns:

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: The Ox who wrote (3601)	8/12/2014 7:21:57 AM
From: The Ox	Read Replies (1) of 8239

Aug 11 (Reuters) - Drug developer Intercept Pharmaceuticals Inc's shares surged as much as 65 percent after the bell on Monday after the company said its drug to treat liver disease caused by fat buildup was effective in mid-stage trials. The drug, obeticholic acid, was tested in patients with non-alcoholic steatohepatitis (NASH), a form of liver inflammation, for which there is no approved treatment. The company said on Monday liver scarring did not worsen in 46 percent of NASH patients who were given the drug, compared with 21 percent in the placebo group. Intercept said on Jan. 9 it had stopped the trial after the drug showed statistically significant improvement in patients. The company's shares quadrupled on that day but lost some of those gains in the past few months as investors raised questions about the drug's side-effects and awaited full clinical results of the trial. "The fear that investors had regarding the safety of the drug have now been put to rest with this update," Oppenheimer analyst Akiva Felt told Reuters. "The statistically significant results of the trial are also a positive new development." The company said it plans to start late-stage trials for the drug in the first half of 2015. The drug is also being tested as a treatment for primary biliary cirrhosis, an autoimmune disease in which bile ducts in the liver are destroyed. Intercept also posted a profit in the second quarter ended June 30 compared with a loss a year earlier, helped by a one-time gain related to revaluation of warrants. Intercept's shares were up 53 percent at $358.07 after the bell.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next